Arch Therapeutics Net income (Q2, 2019)170 K
Arch Therapeutics EBIT (Q2, 2019)-1.5 M
Arch Therapeutics Cash, 31-Mar-20192 M

Arch Therapeutics Funding

Summary Metrics

Founding Date

2006

Arch Therapeutics total Funding

$5.9 m

Arch Therapeutics latest funding size

$3 m

Time since last funding

4 years ago
Arch Therapeutics's latest funding round in July 2015 was reported to be $3 m. In total, Arch Therapeutics has raised $5.9 m

Arch Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

R&D expense

218.9k1.5m1.8m1.7m2.1m2.9m

General and administrative expense

1.5m3.1m3.7m4.4m5.2m4.6m

Operating expense total

1.7m4.6m5.5m6.1m7.3m7.4m

Depreciation and amortization

1.5k

EBIT

(1.7m)(4.6m)(5.5m)(6.1m)(7.3m)(7.4m)

Interest expense

108.9k111.1k377.8k276.7k52.4k

Net Income

(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

R&D expense

257.2k487.1k320.3k399.7k402.5k525.1k414.0k386.3k438.6k349.3k709.9k534.6k580.9k1.0m634.0k589.2k628.8k

General and administrative expense

523.4k808.5k826.0k870.4k853.2k813.1k865.5k868.4k1.3m1.0m1.5m1.3m1.0m999.4k986.1k1.2m878.6k

Operating expense total

780.7k1.3m1.1m1.3m1.3m1.3m1.3m1.3m1.7m1.4m2.2m1.8m1.6m2.0m1.6m1.8m1.5m

EBIT

(780.7k)(1.3m)(1.1m)(1.3m)(1.3m)(1.3m)(1.3m)(1.3m)(1.7m)(1.4m)(2.2m)(1.8m)(1.6m)(2.0m)(1.6m)(1.8m)(1.5m)

Interest expense

27.8k27.8k27.8k27.8k50.6k134.3k143.7k66.8k33.1k25.6k26.8k

Net Income

(808.4k)(8.4m)410.8k379.1k(454.8k)(1.9m)(1.2m)(1.3m)(1.8m)(1.4m)(1.9m)(1.8m)389.2k(1.6m)(2.2m)(2.6m)170.0k

Arch Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

557.3k833.5k4.0m5.0m6.0m4.7m

Accounts Receivable

50.0m

Inventories

19.6k43.5k42.9k107.8k85.3k

Current Assets

1.6m877.0k4.0m5.1m6.1m4.8m

PP&E

322.07.2k17.3k

Total Assets

1.6m877.0k4.0m5.1m6.1m4.8m

Accounts Payable

314.8k175.8k231.8k374.9k264.9k160.9k

Short-term debt

944.7k

Current Liabilities

455.6k2.7m1.3m1.9m433.5k288.4k

Non-Current Liabilities

944.7k5.0m1.2m104.5k3.4m3.2m

Total Debt

944.7k

Total Liabilities

1.4m7.8m2.5m2.0m3.9m3.5m

Additional Paid-in Capital

4.8m5.8m17.2m24.7m31.6m35.5m

Retained Earnings

(12.8m)(15.7m)(21.7m)(29.5m)(34.3m)

Total Equity

1.5m3.2m2.2m1.4m

Debt to Assets Ratio

0.6 x

Financial Leverage

2.6 x1.6 x2.7 x3.6 x

Arch Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)

Depreciation and Amortization

586.0322.01.5k5.3k

Inventories

(16.3k)(13.8k)551.0(64.9k)85.3k

Accounts Payable

56.3k(138.9k)55.9k137.4k(110.0k)(103.9k)

Cash From Operating Activities

(1.3m)(3.3m)(4.2m)(4.7m)(5.6m)(5.9m)

Purchases of PP&E

(8.7k)(15.4k)

Cash From Investing Activities

(8.7k)(15.4k)

Cash From Financing Activities

1.9m3.6m7.4m5.8m6.6m4.6m

Interest Paid

98.3k

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(808.4k)(9.2m)(8.8m)379.1k(454.8k)(1.9m)(1.2m)(2.4m)(4.2m)(1.4m)(3.3m)(5.0m)389.2k(1.2m)(3.4m)(2.6m)(2.4m)

Depreciation and Amortization

322.0119.0477.0835.0724.01.9k3.6k1.8k3.6k

Accounts Payable

(5.2k)(210.6k)(148.8k)118.4k28.3k323.9k36.1k(96.1k)21.3k(102.6k)(247.8k)(168.8k)24.4k52.6k(81.7k)(30.3k)14.7k

Cash From Operating Activities

(611.9k)(1.6m)(2.4m)(850.8k)(1.8m)(2.6m)(1.1m)(2.3m)(3.7m)(1.4m)(3.4m)(4.4m)(1.1m)(2.7m)(4.1m)(1.3m)(2.7m)

Purchases of PP&E

(4.3k)(4.3k)(4.3k)(3.5k)(9.9k)(15.5k)

Cash From Investing Activities

(4.3k)(4.3k)(4.3k)(3.5k)(9.9k)(15.5k)

Cash From Financing Activities

1.0m3.7m3.6m800.0k1.6m5.1m40.0k5.4m130.6k5.6m5.5m63.4k63.4k4.6m32.4k32.4k

Interest Paid

Income Taxes Paid

Arch Therapeutics Ratios

USDY, 2019

Financial Leverage

-12.1 x